IQVIA Holdings Inc. ($IQV) Stock Forecast: Down 5.7% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc. (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The company leverages data, technology, and expertise to help clients drive healthcare forward.

Why is IQVIA Holdings Inc. going down?

IQV stock is down 5.7% on May 20, 2026 14:11

• The bearish movement in IQV's stock could be linked to CFRA downgrading its rating on the shares from Buy to Hold, potentially creating investor uncertainty and selling pressure.
• Despite IQVIA's strong Q1 earnings showing data strength and AI ambitions, the market reaction might have been influenced by the moderation in the stock rating, causing a shift in investor sentiment.
• The announcement of Labcorp's new AI-powered app for lab results interpretation could have negatively impacted IQV's stock, as investors may perceive increased competition or technological advancements in the healthcare data analytics field.
• IQVIA's decision to significantly increase its share repurchase program signals confidence in its financial health and future growth prospects, but the market might be reacting cautiously to this move amidst broader market uncertainties and the recent rating downgrade.

IQV Price Chart

IQV Technical Analysis

IQV News

New Labcorp app uses OpenAI to explain your lab results

Labcorp has launched MyLabcorp, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The HIPAA-compliant app integrates Labcorp test results with OpenAI-powered explanations and clinically reviewed educational content. This initiative aims to address the growing consumer demand for clearer health information by providing personalized insights and facilitating more informed conversations with healthcare providers.

https://www.stocktitan.net/news/LH/labcorp-launches-my-labcorp-tm-a-new-ai-powered-mobile-app-designed-xbgjlguyo99e.html

Research Alert: CFRA Moderates Rating On Shares Of Iqvia Holdings Inc. To Hold From Buy

CFRA has moderated its rating on shares of Iqvia Holdings Inc. from Buy to Hold. This announcement comes alongside Unity Software's recent Q4 earnings report, which showed the company's revenue increased by 35% year-over-year to $609 million, although it reported a quarterly loss of 66 cents per share.

https://www.moomoo.com/news/post/70269513/research-alert-cfra-moderates-rating-on-shares-of-iqvia-holdings

IQVIA Holdings stock (US46266C1053): latest earnings highlight data strength and AI ambitions

IQVIA Holdings recently reported first-quarter 2026 earnings, showcasing strong demand for its clinical research, data analytics, and real-world evidence platforms. The company emphasizes its core business model, which integrates extensive pharmaceutical data with clinical research services, and highlights increasing investments in artificial intelligence to enhance scalability and margins. This positioning makes IQVIA a key player for US healthcare and tech-oriented investors, offering exposure to the digitalization of healthcare and complex R&D.

https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-stock-us46266c1053-latest-earnings-highlight-data/69374969

Certara’s SWOT analysis: life sciences stock faces leadership shift

Certara (NASDAQ:CERT) recently underwent a significant leadership change with Jon Resnick taking over as CEO, posing questions about the company's strategic direction amidst its growth trajectory in the biosimulation market. Despite current undervaluation and muted organic growth, Certara shows potential for accelerated revenue through new leadership's commercial focus and improving biopharma financing. The company's SWOT analysis highlights its established market position and strong EPS growth against challenges like leadership uncertainty and reliance on pharmaceutical R&D spending.

https://m.investing.com/news/swot-analysis/certaras-swot-analysis-life-sciences-stock-faces-leadership-shift-93CH-4698371?ampMode=1

IQVIA Signals Confidence with $3.2 Billion Share Repurchase War Chest

IQVIA Holdings Inc. has significantly increased its share repurchase program by $2 billion, bringing the total authorization to $3.2 billion. This move signals strong confidence in the company's financial health, future growth, and belief that its stock is undervalued, especially considering an analyst-calculated fair value of $225.58 compared to its trading price of $178.64. The expanded program reinforces IQVIA's consistent capital return strategy, balancing shareholder value with aggressive investments in AI and strategic acquisitions within a changing CRO landscape.

https://briefglance.com/articles/iqvia-signals-confidence-with-32-billion-share-repurchase-war-chest

Trending Today

Monero ($XMR) Crypto Forecast: Down 5.9% Today

Leggett & Platt Incorporated ($LEG) Stock Forecast: Up 6.9% Today

Whirlpool Corporation ($WHR) Stock Forecast: Up 6.6% Today

CarMax Inc ($KMX) Stock Forecast: Up 6.2% Today

Target Corporation ($TGT) Stock Forecast: Up 6.5% Today

GoPro Inc. ($GPRO) Stock Forecast: Up 5.3% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 17.8% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Up 13.6% Today

Copart Inc. ($CPRT) Stock Forecast: Up 4.0% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Up 14.2% Today

IQVIA Holdings Inc. Price History

26.01.2026 - IQV Stock was up 5.2%

• Today's positive movement for IQVIA is linked to its acquisition of drug discovery assets from Charles River Laboratories, enhancing its early-stage research offerings and drug discovery platform.
• The rally was also supported by improved investor sentiment on biotech funding and clinical activity, positioning IQVIA as a resilient business with growth opportunities.
• Despite some concerns about fundamental aspects like revenue growth and free cash flow margin, the market is optimistic about IQVIA's strong 2025 performance projections, including revenue and EPS growth, and collaborations in AI-driven research.
• Overall, IQVIA's bullish momentum reflects investor confidence in its acquisitions, financial performance, and growth potential in healthcare and biotech sectors.

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

12.01.2026 - IQV Stock was down 8.4%

• Amid Q3 earnings strength and upbeat FY2026 guidance, IQVIA Holdings Inc. (IQV) witnessed bearish movement likely attributed to:
• Decline in share price over three years, suggesting potential misvaluation or market influences.
• A recent 26% share price plunge after financial results release, causing investor apprehension.
• Price target cuts by analysts while maintaining a "Moderate Buy" rating, reflecting market uncertainty.
• Share price drop on February 10, indicating short-term selling pressure and market volatility.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

11.01.2026 - IQV Stock was down 5.0%

• IQVIA stock saw significant downward movement during the trading day.
• The collaboration between IQVIA and the Duke Clinical Research Institute aimed at advancing clinical research in obesity and related conditions was well-received by investors.
• Despite the upbeat response to the research partnership, the stock's decline may be linked to a decrease in ownership by Compagnie Lombard Odier SCmA, suggesting waning confidence from some institutional investors.
• The overall market outlook for IQVIA is optimistic, with analysts upholding a "Moderate Buy" consensus rating and an average price target of $239.87, indicating potential growth despite today's market performance.

06.03.2026 - IQV Stock was up 0.2%

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

27.01.2026 - IQV Stock was up 5.2%

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

23.03.2026 - IQV Stock was down 9.0%

• The bearish movement in IQV's stock today could be attributed to profit-taking by investors after a period of sustained growth.
• The positive news surrounding Royalty Pharma's dividend approval and partnership with Johnson & Johnson may have diverted some investor attention away from IQVIA Holdings Inc.
• The initiation of coverage by BMO Capital with an Outperform rating might have raised expectations for IQV's stock, leading to a sell-off as investors locked in profits.
• The Google Discover Core Update emphasizing personalized news feeds on IQVIA Holdings Inc. could have triggered algorithmic trading or increased volatility in the stock as investors digested the implications of the update.

05.04.2026 - IQV Stock was up 10.0%

• IQVIA reported strong first-quarter 2026 financial results, with revenue increasing by 8.4% year-over-year to $4,151 million and Adjusted Diluted Earnings per Share up by 7.4%. This positive performance was driven by strong results in both Commercial Solutions and Research & Development Solutions.
• Despite exceeding earnings and revenue forecasts, the stock initially dipped in pre-market trading due to investor concerns. This could be attributed to market volatility and increased competition in the industry.
• IQVIA's strong performance was fueled by AI solutions, new drug launches, and strategic partnerships, along with aggressive share repurchases. The company's focus on innovation and growth strategies seems to be resonating well with investors, leading to a bullish market movement for the stock.

05.04.2026 - IQV Stock was up 5.2%

• IQVIA reported strong first-quarter 2026 financial results, exceeding revenue and earnings expectations, driven by robust performance in Commercial Solutions and Research & Development Solutions.
• Despite beating forecasts and reaffirming its full-year guidance, IQV's stock initially dipped in pre-market trading due to investor concerns, possibly related to market volatility and competition worries.
• The market movement turned bullish as investors likely recognized the company's strong fundamentals, including its AI solutions, new drug launches, and strategic partnerships, leading to a positive outlook for continued growth.
• Integration of AI in life sciences operations, as highlighted in industry reports, could have also positively influenced investor sentiment towards IQVIA, showcasing the company's innovative approach and potential for further advancements in the sector.

06.04.2026 - IQV Stock was up 11.2%

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.

20.04.2026 - IQV Stock was down 5.7%

• The bearish movement in IQV's stock could be linked to CFRA downgrading its rating on the shares from Buy to Hold, potentially creating investor uncertainty and selling pressure.
• Despite IQVIA's strong Q1 earnings showing data strength and AI ambitions, the market reaction might have been influenced by the moderation in the stock rating, causing a shift in investor sentiment.
• The announcement of Labcorp's new AI-powered app for lab results interpretation could have negatively impacted IQV's stock, as investors may perceive increased competition or technological advancements in the healthcare data analytics field.
• IQVIA's decision to significantly increase its share repurchase program signals confidence in its financial health and future growth prospects, but the market might be reacting cautiously to this move amidst broader market uncertainties and the recent rating downgrade.